If the medical board does not provide the expiration date for a practitioner's board certification, the organization must verify and document that the board certification is current within 180 calendar days of the credentialing decision date.
Here are some of the most frequently asked questions about NCQA’s various programs. If you don’t see what you are looking for in one of the entries below, you can ask a question through My NCQA.
If the medical board does not provide the expiration date for a practitioner's board certification, the organization must verify and document that the board certification is current within 180 calendar days of the credentialing decision date.
No. NCQA will not make any changes to the vaccine requirements for HEDIS 2014. As indicated by the CDC, "Single-component DTaP, IPV, HepB, and Hib vaccines and other age-appropriate licensed combination vaccines are available to complete series begun with Pentacel or Pediarix. Currently, there is a sufficient supply of these products to meet the anticipated demand." You can find additional information in the Guidance for Vaccinating Children during the 2013 Pentacel, Daptacel and Pediarix Shortage article at http://www.cdc.gov/vaccines/vac-gen/shortages/downloads/pentacel-guidance.pdf.
NCQA is aware that recent guidelines recommend pap tests NOT be performed for women under 21 years of age under general circumstances. However, for the PPC measure, a pap test will remain in the specifications as a way to determine that postpartum care occurred. NCQA allows documentation of only a Pap test because this test indicates that a pelvic exam was performed. This measure includes deliveries in any age group.
NCQA is re-evaluating the PPC measure based on clinical practice guideline updates. Any changes will be included in future HEDIS specifications.
The physician group or IPA may distribute information to its physicians if this language is in the contractual agreement. NCQA does not consider this to be delegation. The organization must provide the required information to the physician group or IPA.
The medication review indicator requires both a medication list and evidence that it was reviewed by the appropriate practitioner. The presence of a medication list with the appropriate practitioner's signature is compliant if it is dated during the measurement year. The practitioner's signature is considered evidence that the medications were reviewed.
All supplemental data requirements are included in General Guideline 39 in the HEDIS 2014 Volume 2 Technical Specification. Customers can find additional information about the supplemental data policy (including FAQs specific to supplemental data) at the following link, http://www.ncqa.org/Newsroom/MediaEvents/HEDIS2014CodeTransitionSupplementalDataUse.aspx.
For Interim evaluation options, if an organization has not finalized a delegation agreement with an intended delegate, NCQA will accept draft agreements and communications between organizations for delegation requirements. NCQA will review and score the draft agreement and communications defining when the agreement will be complete for Elements A (Written Delegation Agreement) and B (Provision of PHI) in the applicable categories (QI, UM, CR, RR). NCQA will also review documented processes and reports for Element D (Predelegation Evaluation). NCQA will score delegation Element C (Review/Approval of Program, Right to Approve and Terminate, Predelegation Agreement) as Not Applicable. NCQA reserves the right to review and score finalized delegation agreements.